Study to Evaluate Safety/Efficacy of a Single Preop Dose of AYX1 Injection to Treat Pain After Knee Replacement Surgery
15. oktober 2018 oppdatert av: Adynxx, Inc.
A Phase 2 Randomized Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of a Single Intrathecal Preoperative Administration of AYX1 Injection in Patients Undergoing Unilateral Total Knee Arthroplasty
The objectives of this study are to evaluate the safety and analgesic efficacy of a single preoperative intrathecal administration of AYX1 Injection in patients undergoing unilateral total knee arthroplasty.
Studieoversikt
Status
Fullført
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
This is a multi-center, Phase 2, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of AYX1 Injection administered intrathecally before surgery in patients undergoing primary unilateral total knee arthroplasty (TKA).
Subjects will be randomized on the day of surgery to receive either intrathecal AYX1 Injection or intrathecal placebo just prior to surgery.
Study assessments will be conducted during the inpatient period through 48 hours; follow-up visits will be performed through Study Day 90.
Studietype
Intervensjonell
Registrering (Faktiske)
210
Fase
- Fase 2
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
Alabama
-
Birmingham, Alabama, Forente stater, 35209
- Alabama Orthopedic Center
-
Sheffield, Alabama, Forente stater, 35660
- Shoals Medical Trials
-
-
Arizona
-
Phoenix, Arizona, Forente stater, 85023
- Arizona Research Center
-
-
California
-
Encinitas, California, Forente stater, 92024
- CORE Orthopaedic Medical Center
-
-
Florida
-
Pensacola, Florida, Forente stater, 32503
- Pensacola Research Consultants
-
Tamarac, Florida, Forente stater, 33321
- Phoenix Clinical Research
-
-
Mississippi
-
Jackson, Mississippi, Forente stater, 39202
- Mississippi Sports Medicine
-
-
Ohio
-
Columbus, Ohio, Forente stater, 43210
- The Ohio State University Wexner Medical Center
-
-
Pennsylvania
-
Indiana, Pennsylvania, Forente stater, 15701
- Antria, Inc.
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
40 år og eldre (Voksen, Eldre voksen)
Tar imot friske frivillige
Nei
Kjønn som er kvalifisert for studier
Alle
Beskrivelse
Inclusion Criteria:
- Scheduled to undergo primary unilateral TKA with spinal anesthesia for painful osteoarthritis without congenital knee pathology
- American Society of Anesthesiologists Physical Status Classification System ≤ 3
- Medically stable as determined by the Investigator based on pre-study medical history, physical examination, clinical laboratory tests, and 12-lead electrocardiogram (ECG) findings
- Body Mass Index of 18-45 kg/m2
- Stable medical regimen for at least 1 week before randomization
- Able to read and understand study instructions in English, and willing and able to comply with all study procedures
Exclusion Criteria:
- More than 2 other current focal areas of pain, any pain areas greater in intensity than the target knee, or any other active chronic pain conditions that would compromise operative knee pain evaluation
- Inflammatory arthridities (e.g., rheumatoid arthritis, lupus, ankylosing spondylitis, psoriatic arthritis), with the exception of clinically stable/non-active gout that does not affect the knee and does not interfere with walking
- Surgery in either knee within 3 months prior to randomization, or surgery in either knee greater than 3 months prior to randomization with residual symptoms that would interfere with post-TKA study assessments; use of cryoneurolysis (including Iovera) on the current operative knee region within the 6 months prior to randomization and/or at any time through the duration of the study
- Planned use of general anesthesia or potent inhalational agents, peripheral nerve block (e.g., femoral nerve block), neuroaxial (intrathecal or epidural) opioids, preoperative extended release/long acting opioids, or any use of ketamine preoperatively and/or at any time through the duration of the study
- Use of more than 40 mg per day (on average) of oral morphine or its equivalent within 1 month prior to randomization
- Use of gabapentin or pregabalin within 1 week prior to randomization or planned use post-operatively through Day 28
- Use of systemic corticosteroids (IV or oral) within 3 months prior to randomization through Day 28; planned use of intra-articular steroid injections in the operative knee from the time of randomization through Day 28
- Current neurologic disorder, which could confound the assessment of pain (e.g., Parkinson's, Multiple Sclerosis)
- Untreated or inadequately treated (in the opinion of the Investigator) active depression
- Mini Mental State Exam score < 24 at screening
- History of alcohol-related complications within 1 year of randomization including, but not limited to, alcoholic withdrawal seizures, hallucinations, delirium tremens or detoxification treatment
- Known or suspected history of illicit drug use within 1 year before randomization, or current or planned use of marijuana (including medical approved use) within 1 month before randomization and/or through the duration of the study
- Any confirmed malignancy within the past year, with the exception of basal cell carcinoma or uncomplicated or stable skin cancers documented to not require further or immediate treatment
- Women who are pregnant or nursing
- Previous participation in any study involving AYX1 Injection
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Trippel
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Placebo komparator: Placebo Injection 6 mL
Single Intrathecal (spinal) administration of Placebo Injection (6 mL) just prior to intrathecal administration of spinal anesthetic for knee surgery
|
6 mL solution for intrathecal injection; vehicle formulation designed to mimic AYX1 Injection (with no active drug)
|
|
Eksperimentell: AYX1 Injection 660 mg/6 mL
Single Intrathecal (spinal) administration of AYX1 Injection (660 mg in 6 mL) just prior to intrathecal administration of spinal anesthetic for knee surgery.
|
6 mL solution for intrathecal injection with 660 mg of AYX1 (Brivoligide)
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Mean pain with walking during the 15 meter walk test Day 7 to Day 28
Tidsramme: 7-28 days post-surgery
|
Mean pain rating on the Numerical Rating Scale (NRS) with walking during the 15 meter walk test during the outpatient period from Day 7 to Day 28
|
7-28 days post-surgery
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Percentage of subjects with NRS pain score ≥ 4 during the 15 meter walk at Day 90
Tidsramme: at 90 days post-surgery
|
Percentage of subjects with the Numerical Rating Scale (NRS) pain score ≥ 4 during the 15 meter walk at Day 90
|
at 90 days post-surgery
|
|
Mean pain rating (NRS) at rest Day 7 to Day 28
Tidsramme: 7-28 days post-surgery
|
Mean pain rating with the Numerical Rating Scale (NRS) at rest Day 7 to Day 28
|
7-28 days post-surgery
|
|
Total use of postoperative opioid medications (morphine equivalents) post-discharge to Day 90
Tidsramme: post-hospital discharge through 90 days post-surgery
|
Total use of postoperative opioid medications (morphine equivalents) post-discharge to Day 90
|
post-hospital discharge through 90 days post-surgery
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Etterforskere
- Studieleder: Donald C Manning, MD, PhD, Adynxx, Inc.
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Faktiske)
20. februar 2017
Primær fullføring (Faktiske)
23. oktober 2017
Studiet fullført (Faktiske)
19. desember 2017
Datoer for studieregistrering
Først innsendt
17. juni 2016
Først innsendt som oppfylte QC-kriteriene
17. juni 2016
Først lagt ut (Anslag)
21. juni 2016
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
17. oktober 2018
Siste oppdatering sendt inn som oppfylte QC-kriteriene
15. oktober 2018
Sist bekreftet
1. oktober 2018
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- ADYX-004
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
NEI
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Ja
Studerer et amerikansk FDA-regulert enhetsprodukt
Nei
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .